RATIONALE AND OBJECTIVES:The aim of this study was to assess (1) automated analysis methods versus manual evaluation by human experts of three-dimensional proton magnetic resonance spectroscopic imaging (MRSI) data from patients with prostate cancer and (2) the contribution of spatial information to decision making.
MATERIALS AND METHODS: Three-dimensional proton MRSI was applied at 1.5 T. MRSI data from 10 patients with histologically proven prostate adenocarcinoma, scheduled either for prostatectomy or intensity-modulated radiation therapy, were evaluated. First, two readers manually labeled spectra using spatial information to identify the localization of spectra and neighborhood information, establishing the reference set of this study. Then, spectra were labeled again manually in a blinded and randomized manner and evaluated automatically using software that applied spectral line fitting as well as pattern recognition routines. Statistical analysis of the results of the different approaches was performed.
RESULTS: Altogether, 1018 spectra were evaluable by all methods. Numbers of evaluable spectra differed significantly depending on patient and evaluation method. Compared to automated analysis, the readers made rather binary decisions, using information from neighboring spectra in ambiguous cases, when evaluating MRSI data as a whole. Differences between anatomically blinded and unblinded evaluation were larger than differences between evaluations using blinded data and automated techniques.
CONCLUSIONS: An automated approach, which evaluates each spectrum individually, can be as good as an anatomy-blinded human reader. Spatial information is routinely used by human experts to support their final decisions. Automated procedures that consider anatomic information for spectral evaluation will enhance the diagnostic impact of MRSI of the human prostate.
Written by:
Zechmann CM, Menze BH, Kelm BM, Zamecnik P, Ikinger U, Giesel FL, Thieke C, Delorme S, Hamprecht FA, Bachert P. Are you the author?
Department of Radiology, German Cancer Research Center, Heidelberg, Germany.
Reference: Acad Radiol. 2012 Jun;19(6):675-84.
doi: 10.1016/j.acra.2012.02.014
PubMed Abstract
PMID: 22578226
UroToday.com Prostate Cancer Section